
Friday, February 28, 2025 1:06:52 PM
Wells Fargo analyst Tiago Fauth maintains Verona Pharma (VRNA) with a Overweight and raises the price target from $74 to $93.
Nice to see such an increase in the target.

Recent VRNA News
- Verona Pharma to Report First Quarter 2025 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 04/15/2025 10:00:00 AM
- Form 8-K - Current report • Edgar (US Regulatory) • 03/28/2025 11:08:13 AM
- Verona Pharma Announces Amended Strategic Financing with Oaktree and OMERS • GlobeNewswire Inc. • 03/28/2025 11:00:00 AM
- Form ARS - Annual Report to Security Holders • Edgar (US Regulatory) • 03/18/2025 08:34:24 PM
- Form DEF 14A - Other definitive proxy statements • Edgar (US Regulatory) • 03/18/2025 08:22:01 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 03/14/2025 12:15:16 AM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 03/12/2025 08:23:23 PM
- Form S-8 - Securities to be offered to employees in employee benefit plans • Edgar (US Regulatory) • 02/27/2025 09:31:18 PM
- Form 10-K - Annual report [Section 13 and 15(d), not S-K Item 405] • Edgar (US Regulatory) • 02/27/2025 01:46:22 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 02/27/2025 11:07:16 AM
- Verona Pharma Reports Fourth Quarter and Full Year 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 02/27/2025 11:00:00 AM
- Verona Pharma Announces March 2025 Investor Conference Participation • GlobeNewswire Inc. • 02/18/2025 11:00:00 AM
- Verona Pharma to Report Fourth Quarter and Full Year 2024 Financial Results and Provide Corporate Update • GlobeNewswire Inc. • 02/13/2025 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 02/04/2025 09:30:17 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 01/07/2025 11:00:36 AM
- Verona Pharma Reports Strong Ohtuvayre™ Launch and Provides Preliminary Fourth Quarter and Full Year 2024 Financial Highlights • GlobeNewswire Inc. • 01/07/2025 11:00:00 AM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/26/2024 11:34:08 PM
- Form 144 - Report of proposed sale of securities • Edgar (US Regulatory) • 11/25/2024 09:42:08 PM
- Verona Pharma Announces December 2024 Investor Conference Participation • GlobeNewswire Inc. • 11/19/2024 07:00:00 AM
- Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend] • Edgar (US Regulatory) • 11/14/2024 02:47:59 PM
- Form 4 - Statement of changes in beneficial ownership of securities • Edgar (US Regulatory) • 11/07/2024 11:56:12 PM
- Verona Pharma to Present at Jefferies London Healthcare Conference • GlobeNewswire Inc. • 11/05/2024 07:00:00 AM
- Form 10-Q - Quarterly report [Sections 13 or 15(d)] • Edgar (US Regulatory) • 11/04/2024 01:47:12 PM
- Form 8-K - Current report • Edgar (US Regulatory) • 11/04/2024 11:06:03 AM
- Verona Pharma Reports Third Quarter 2024 Financial Results and Provides Corporate Update • GlobeNewswire Inc. • 11/04/2024 07:00:00 AM
Opus Holdings Unveils Powerhouse Leadership Team to Drive Aggressive Growth and Transform Market Trajectory • CATV • Apr 22, 2025 8:30 AM
Glidelogic Corp. (OTCQB: GDLG) Highlights Independent SOTA Evaluation of ResearchMind Platform • GDLG • Apr 22, 2025 6:54 AM
UAV Corp to Launch Inflation Test of SA-70 Airship This Week-A Gateway to High-Value Government and Defense Contracts • UMAV • Apr 21, 2025 1:30 PM
VAYK Corrects Major Clerical Error to Report $668K Operating Revenue for 2024 • VAYK • Apr 17, 2025 9:00 AM
UAV Corp Names David Dugas as President and Chief Operating Officer • UMAV • Apr 17, 2025 8:30 AM
Yuengling's Ice Cream Corporation (OTC: YCRM), Doing Business as ReachOut, Files 2024 10-K With Profitability, Growth, and Corporate Transformation in Focus • YCRM • Apr 16, 2025 11:07 AM